首页
登录
职称英语
The European Commission said on Thursday it would toughen the regulation of
The European Commission said on Thursday it would toughen the regulation of
游客
2023-11-17
31
管理
问题
The European Commission said on Thursday it would toughen the regulation of medical devices as a result of concerns raised by breast implants produced by the defunct French company PIP, even as a scientific expert review it ordered concluded there was currently "insufficient evidence" that women using its products faced greater health risks than others.
John Dalli, health and consumer policy commissioner, pledged to examine surveillance and operation of the "notified bodies" that scrutinise medical devices across the EU in a current review of legislation, stressing: "The capacity to detect and minimise the risk of fraud must be increased."
His comments followed an official report released on Wednesday in France that called for national and EU-wide co-operation including random inspections and sampling of medical devices to prevent a repeat of the fraudulent use of substandard non-medical-grade silicone by PIP in implants sold to up to 400,000 women around the world.
Xavier Bertrand, France’s minister of health, called for enhanced action in France and across Europe in the wake of the study, which highlighted that Afssaps, the French medical regulator, did not inspect PIP from 2001 until a tip-off led officials to inspect and close down the company in 2010. Jean-Claude Mas, its founder, is under police investigation for manslaughter.
Mr. Bertrand has pledged to hire more health inspectors and undertake random checks on medical device companies following growing concerns over its regulatory system highlighted by the widespread use of PIP’s substandard breast implants.
A French decision at the end of last year to offer all women free removal of PIP implants triggered similar proposals in the UK, Germany and the Czech Republic and has helped spark a fresh debate over tougher EU regulation of medical devices, which are subject to far less scrutiny than pharmaceuticals.
However, a review released on Thursday by the EU’s own Scientific Committee on Emerging and Newly Identified Health Risks concluded: "Breast implants can fail, regardless of manufacturer, and the probability of failure increases with time since implantation. In most cases, breast implant failure appears to be without identifiable health consequences for the patient with the exception of possible local complications."
It stressed that limited data meant that while there was no link between breast implants and cancer, there was a need for further work to understand the specific risks from the PIP products.
Mr. Bertrand has endorsed calls for a parliamentary inquiry in France as well as a report from the country’s social affairs inspectorate, mirroring similar moves that led to tough new requirements for the pharmaceutical industry introduced last year in the wake of concerns about Servier’s drug Mediator.
Medical device manufacturers have called for reforms to ensure that the national "notified bodies" which audit the quality of their products across Europe are of a consistently high standard, while cautioning that tough new regulatory requirements could harm the EU’s competitive advantage.
The French study showed that Afssaps had received multiple warnings over the relatively high failure rate of PIP implants compared with those made by other companies, even though the overall proportion remained modest.
From Financial Times, February 2, 2012 [br] According to the passage, "notified bodies" in Paragraph 2 are responsible for______.
选项
A、proposing legislation, implementing decisions in European Union
B、producing and marketing the medical devices across the EU
C、providing some scientific advice to the European Commission
D、assessing whether a product meets certain preordained standards
答案
D
解析
本题为语义题。根据第二段“…‘notified bodies’that scrutinise medical devices…”和倒数第二段“‘notified bodies’which audit the quality of their products…”可知D正确;A是European Commission的职责;B是制药公司的职责;C是Scientific Committee on Emerging and Newly Identified Health Risks的职责。
转载请注明原文地址:https://tihaiku.com/zcyy/3193973.html
相关试题推荐
ThedisputebetweentheEuropeanUnionandtheUnitedStatesismainlyabout[br
ThedisputebetweentheEuropeanUnionandtheUnitedStatesismainlyabout[br
AbreakthroughintheprovisionofenergyfromthesunfortheEuropeanEco
Inthe1920sdemandforAmericanfarmproductsfell,asEuropeancountries
Inthe1920sdemandforAmericanfarmproductsfell,asEuropeancountries
Inthe1920sdemandforAmericanfarmproductsfell,asEuropeancountries
TheEuropeanUnionhadnotapprovedanumberofgeneticallymodifiedcropsu
TheEuropeanUnionhadnotapprovedanumberofgeneticallymodifiedcropsu
TheEuropeanUnionhadnotapprovedanumberofgeneticallymodifiedcropsu
TheEuropeanUnionhadnotapprovedanumberofgeneticallymodifiedcropsu
随机试题
PrisonStudiesA)Manywhotodayhearmesomewhere
[originaltext]TheJapaneseMinistryofHealth,LabourandWelfarereleasedthe
杜氏利什曼原虫的重要保虫宿主是A.牛 B.羊 C.猪 D.猫 E.犬
引起肝硬化腹水的原因,下列哪一项是错误的()A.小叶下静脉受压 B.肝
A."火山口征" B."鱼刺征" C."腊肠征" D.短轴图像上可见多环"
在我国实施辅助生殖技术,符合卫生部制定的伦理原则的是A、实施非医学需要的性别选择
三阴三阳经中,下列哪条经脉行于头两侧部A.厥阴经 B.太阴经 C.阳明经
根据《公司法》的规定,以下说法正确的有()。 Ⅰ.不管是有限公司还是股份公司
下列关于数据分组的说法,不正确的是()。A.数据分组的组数一般与数据本身的特点及
黄连治痢疾属于七情配伍中的A.相反 B.相须 C.相使 D.单行 E.相
最新回复
(
0
)